Immunotherapy and radiation combo may curb liver cancer return
NCT ID NCT07352007
First seen Jan 22, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tests whether giving a combination of an immunotherapy drug (sintilimab) and targeted radiation before surgery can lower the chance of liver cancer coming back. About 110 adults with resectable liver cancer will be randomly assigned to receive either the combination treatment before surgery or surgery alone. After surgery, both groups will continue immunotherapy for up to a year to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ShandongShandong Cancer Hospital and Institute
Jinan, Shandong, China
Conditions
Explore the condition pages connected to this study.